Investigational drug · Phase 3
Fluoropyrimidine
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma, Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
221
Any phase or sponsor naming "Fluoropyrimidine"
First trial start
2022
Feb 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fluoropyrimidine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Neoplasms
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Fluoropyrimidine" as an intervention, largest first.
- Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerPivotal-lookingStatus unknown
Velindre NHS TrustGovernment (non-federal)
NCT00182715 · 2,421 participants (planned) · Start Mar 2005 · Primary completion May 2009
Drug: cetuximab; capecitabine and 3 more · For: Colorectal Cancer
Sites: Cork, Ireland; Dublin, Ireland; Galway, Ireland · 82 sites in all
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02872116 · 2,031 participants · Start Oct 12, 2016 · Primary completion May 27, 2020
Drug: Nivolumab; Ipilimumab and 4 more · For: Gastric Cancer; Gastroesophageal Junction Cancer; Esophageal Adenocarcinoma
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 179 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT04194957 · 1,440 participants (planned) · Start Jan 15, 2020 · Primary completion Jan 2021
Drug: Fluoropyrimidine (capecitabine or 5-fluorouracil); Fluoropyrimidine (capecitabine or 5-fluorouracil) and 1 more · For: Neoplasms
Sites: Amsterdam, Netherlands
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02324452 · 1,103 participants · Start Mar 2015 · Primary completion Jan 2018
Drug: Fluoropyrimidine (capecitabine or 5-fluorouracil) · For: Neoplasms
Sites: Amsterdam, Netherlands; Assen, Netherlands; Breda, Netherlands · 17 sites in all
- A Study in Second Line Metastatic Colorectal CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01183780 · 1,072 participants · Start Dec 2, 2010 · Primary completion Jul 17, 2014
Drug: Ramucirumab; Placebo and 3 more · For: Colorectal Cancer
Sites: Sedona, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 213 sites in all
- Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by SurgeryPivotal-lookingStatus unknown
University of BirminghamAcademic, hospital or other
NCT00647530 · 1,053 participants · Start May 15, 2008 · Primary completion Dec 23, 2016
Drug: panitumumab; capecitabine and 2 more · For: Colorectal Cancer
Sites: Birmingham, United Kingdom; Gateshead, United Kingdom; Huddersfield, West Yorks, United Kingdom · 10 sites in all
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02291289 · 1,044 participants · Start Apr 17, 2015 · Primary completion May 31, 2019
Drug: Cetuximab; FOLFOX induction regimen and 9 more · For: Colorectal Cancer
Sites: Buenos Aires, Argentina; La Rioja, Argentina; Viedma Rio Negro, Argentina · 154 sites in all
- Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal CancerPivotal-lookingRecruiting
Karolinska University HospitalAcademic, hospital or other
NCT04460352 · 1,020 participants (planned) · Start Nov 27, 2020 · Primary completion Dec 31, 2026
Drug: Carboplatin, paclitaxel; Carboplatin, paclitaxel and 2 more · For: Esophageal Squamous Cell Carcinoma
Sites: Montreal, Canada; Dublin, Ireland; Oslo, Norway · 12 sites in all
- Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)Not yet recruiting
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT07858500 · 1,000 participants (planned) · Start Jan 31, 2027 · Primary completion Jun 30, 2029
Drug: Zolbetuximab Exposure; Platinum-based Chemotherapy Exposure and 2 more · For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer and 1 more
Sites: Alberta, Canada
- Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction CarcinomaPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03777657 · 997 participants · Start Dec 13, 2018 · Primary completion Feb 28, 2023
Drug: Tislelizumab; Placebo and 4 more · For: Gastric, or Gastroesophageal Junction Adenocarcinoma
Sites: Sacramento, California; Newnan, Georgia; Columbus, Ohio · 149 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Thymidylate synthase expression identifies hepatocellular carcinoma vulnerable to fluoropyrimidine-based therapy.
Choi H, Lee Y, Lee J, et al. · Genes Dis 2027
- 5-Fluorouracil-induced severe hyperlactatemic encephalopathy during chemotherapy for advanced colorectal cancer: Case reports and literature review.
Jin Y, Xiang X, Zhang W, et al. · Exp Ther Med 2026
- Integrative machine learning for identifying transcriptomic signatures of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Mirghayed MMR, Soror AA, Rezaei A, et al. · Biochem Biophys Rep 2026
- Unexpected favorable response of stage IV gastric adenocarcinoma to sintilimab combined with chemotherapy: A case report.
Han J, Zhu Z, Huang L, et al. · Oncol Lett 2026
- Kinetics, radical chemistry and machine-learning-optimized abatement of capecitabine by UV/peroxymonosulfate: simultaneous micropollutant removal and attenuation of disinfection by-products formation potential.
Feng ZH, Yin Y, Zhou ZY, et al. · Environ Res 2026
- Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.
Inagaki C, Oki E, Ando K, et al. · ESMO Gastrointest Oncol 2026
Also in development for Colorectal Neoplasms
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- SGM-101Phase 31 trial
Surgimab · Colorectal Neoplasms
- BLU-924SAR449336Phase 21 trial
Blueprint Medicines Corporation · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
- E7386Phase 21 trial
Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.